{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:56:02Z","timestamp":1789890962475,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["23XD1420600"],"award-info":[{"award-number":["23XD1420600"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172621"],"award-info":[{"award-number":["82172621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473381"],"award-info":[{"award-number":["82473381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203106"],"award-info":[{"award-number":["82203106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["823B2066"],"award-info":[{"award-number":["823B2066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972375"],"award-info":[{"award-number":["81972375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-MSDZD2021-0230"],"award-info":[{"award-number":["Y-MSDZD2021-0230"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013285","name":"Program for Professor of Special Appointment Eastern Scholar at Shanghai Institutions of Higher Learning","doi-asserted-by":"publisher","award":["TP2022051"],"award-info":[{"award-number":["TP2022051"]}],"id":[{"id":"10.13039\/501100013285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.xcrm.2025.102018","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T10:42:25Z","timestamp":1741344145000},"page":"102018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study"],"prefix":"10.1016","volume":"6","author":[{"given":"Tingwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102018_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamaoncol.2018.4836","article-title":"Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality","volume":"5","author":"Tilki","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib2","article-title":"Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk\/locally Advanced Prostate Cancer: An Individual Patient Data Analysis of RCTs from the ICECaP Consortium","volume":"43","author":"Ravi","year":"2023","journal-title":"ESMO"},{"key":"10.1016\/j.xcrm.2025.102018_bib3","series-title":"Clinical Practice Guidelines in Oncology Prostate Cancer","year":"2023"},{"key":"10.1016\/j.xcrm.2025.102018_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s44178-024-00118-4","article-title":"CACA guidelines for holistic integrative management of prostate cancer","volume":"3","author":"Dai","year":"2024","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2025.102018_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102018_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","year":"2015","journal-title":"Cellule"},{"key":"10.1016\/j.xcrm.2025.102018_bib8","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102018_bib10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102018_bib12","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced \"BRCAness\" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2025.102018_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2025.102018_bib15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102018_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","article-title":"Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer","volume":"80","author":"Berchuck","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102018_bib18","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib19","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pros.24712","article-title":"Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer","volume":"84","author":"Marshall","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.xcrm.2025.102018_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102018_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102018_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib25","first-page":"114","article-title":"Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping","volume":"5","author":"Warner","year":"2024","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xcrm.2025.102018_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2024.03.006","article-title":"Genetic interactions reveal distinct biological and therapeutic implications in breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3324\/haematol.2019.240713","article-title":"Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma","volume":"106","author":"Caracciolo","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102018_bib28","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102018_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41523-022-00427-9","article-title":"Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naive gBRCA+ breast cancers","volume":"8","author":"Liu","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102018_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","article-title":"NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.xcrm.2025.102018_bib32","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1158\/1078-0432.CCR-17-1034","article-title":"Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy","volume":"23","author":"Beltran","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib33","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-18-0610","article-title":"Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations","volume":"78","author":"Sowalsky","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2015.08.001","article-title":"Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells","volume":"369","author":"Huo","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2025.102018_bib35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1096\/fj.09-136994","article-title":"Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells","volume":"24","author":"Zhu","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.xcrm.2025.102018_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Franca","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102018_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10555-016-9648-7","article-title":"EMT, cell plasticity and metastasis","volume":"35","author":"Chaffer","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.xcrm.2025.102018_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semcancer.2022.11.001","article-title":"Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer","volume":"87","author":"Ervin","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2025.102018_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1224892","article-title":"The potential of activator protein 1 (AP-1) in cancer targeted therapy","volume":"14","author":"Song","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102018_bib40","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). In U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, ed."},{"key":"10.1016\/j.xcrm.2025.102018_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"10.1016\/j.xcrm.2025.102018_bib42","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","article-title":"Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue","volume":"47","author":"Cooper","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102018_bib44","first-page":"1475","article-title":"Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer","volume":"5","author":"Pan","year":"2024","journal-title":"Medizinrecht"},{"key":"10.1016\/j.xcrm.2025.102018_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12859-020-03924-5","article-title":"Accucopy: accurate and fast inference of allele-specific copy number alterations from low-coverage low-purity tumor sequencing data","volume":"22","author":"Fan","year":"2021","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102018_bib47","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","article-title":"InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines","volume":"100","author":"Li","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2025.102018_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","volume":"1","author":"Chakravarty","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib50","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102018_bib52","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-22-3736","article-title":"Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors","volume":"29","author":"Menssouri","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109665","article-title":"Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer","volume":"36","author":"Tewari","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102018_bib54","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-20-3708","article-title":"BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression","volume":"27","author":"Warner","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.xcrm.2025.102018_bib56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2025.102018_bib57","doi-asserted-by":"crossref","first-page":"D674","DOI":"10.1093\/nar\/gkn653","article-title":"PID: the Pathway Interaction Database","volume":"37","author":"Schaefer","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib58","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-022-32701-6","article-title":"Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity","volume":"13","author":"Westbrook","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102018_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102018_bib60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","article-title":"Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators","volume":"10","author":"Hieronymus","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib61","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102018_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2025.102018_bib63","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102018_bib64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/cncr.31908","article-title":"Germline mutations of\u00a0renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease","volume":"125","author":"Wu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102018_bib65","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:40:18Z","timestamp":1762638018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666379125000916"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102018","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102018"}}